These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Jankovic J; Schwartz K; Vander Linden C Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215 [TBL] [Abstract][Full Text] [Related]
7. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Ondo WG; Shinawi L; Moore S Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966 [TBL] [Abstract][Full Text] [Related]
9. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405 [TBL] [Abstract][Full Text] [Related]
10. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200 [TBL] [Abstract][Full Text] [Related]
11. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis. LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286 [TBL] [Abstract][Full Text] [Related]
12. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
13. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials. Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090 [TBL] [Abstract][Full Text] [Related]
14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S; Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014 [TBL] [Abstract][Full Text] [Related]
16. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088 [TBL] [Abstract][Full Text] [Related]
17. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA; Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. Modi NB; Mittur A; Dinh P; Rubens R; Gupta S Clin Neuropharmacol; 2019; 42(5):149-156. PubMed ID: 31306216 [TBL] [Abstract][Full Text] [Related]
19. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234 [TBL] [Abstract][Full Text] [Related]